ALEC Earnings

ALEC reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 3.26M against an estimate of 3.49M, resulting in a -6.52% surprise. The EPS was -0.34, surpassing the expected -0.42 by 19.05%. The stock experienced a -1.54% price change on the earnings day and a 3.08% change over the next five days, reflecting market reactions to the results.

Following ALEC's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by -1.54% on the day of the release. Over the subsequent five days, it saw a 3.08% change. Historically, ALEC's stock price tends to shift by an average of 4.4% in the 10 days leading up to earnings and 1.7% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate ALEC's annual revenue to reach 3.49M, while the EPS is projected at -0.41. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ALEC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ALEC's stock price typically moves by 4.4% in the 10 days before its earnings and 1.7% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -0.41 and revenue of 3.49M.

The earnings call summary and Q&A session revealed a mixed outlook. Positive aspects include robust Phase II data and a meaningful potential impact of the drug on FTD patients. However, uncertainty remains due to management's unclear responses and lack of specific guidance. The FDA's request for plasma progranulin as a co-primary endpoint adds complexity but doesn't affect study power. Overall, the absence of concrete financial guidance and market cap data leads to a neutral sentiment, suggesting limited short-term stock movement.